

Acta Crystallographica Section C

**Crystal Structure
Communications**

ISSN 0108-2701

Editor: **George Ferguson**

Cocrystals of diastereoisomers of 1,4-dihydropyridine derivatives

Anthony Linden, Miyase G. Gündüz, Rahime Şimşek and Cihat Şafak

Copyright © International Union of Crystallography

Author(s) of this paper may load this reprint on their own web site provided that this cover page is retained. Republication of this article or its storage in electronic databases or the like is not permitted without prior permission in writing from the IUCr.

Cocrystals of diastereoisomers of
1,4-dihydropyridine derivativesAnthony Linden,^{a*} Miyase G. Gündüz,^b Rahime Şimşek^b
and Cihat Şafak^b^aInstitute of Organic Chemistry, University of Zürich, Winterthurerstrasse 190,
CH-8057 Zürich, Switzerland, and ^bDepartment of Pharmaceutical Chemistry,
Faculty of Pharmacy, Hacettepe University, 06100 Ankara, Turkey
Correspondence e-mail: alinden@oci.unizh.ch

Received 1 March 2006

Accepted 2 March 2006


Online 31 March 2006

A mixture of the *RR/SS* and *RS/SR* diastereoisomeric pairs of methyl 4-(2,4-dichlorophenyl)-2,7-dimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate, $C_{19}H_{19}Cl_2NO_3$, forms cocrystals in which there is one unique molecule in the asymmetric unit, but the molecule displays disorder in the region of the 7-position of the quinoline ring system as a result of the random occurrence of the diastereoisomers at the same crystallographic site. A similar arrangement exists in the monohydrate cocrystals that form from a mixture of the *RR/SS* and *RS/SR* diastereoisomeric pairs of methyl 4-(2,4-dichlorophenyl)-2-methyl-7-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate monohydrate, $C_{24}H_{21}Cl_2NO_3 \cdot H_2O$. These compounds belong to a class of 1,4-dihydropyridines whose members have calcium modulatory properties. The 1,4-dihydropyridine rings have the usual shallow boat conformation. In each structure, the 2,4-dichlorophenyl ring is oriented such that the 2-chloro substituent is in a synperiplanar orientation with respect to the 1,4-dihydropyridine ring plane. In each crystal structure, the molecules are linked into chains by $N-H \cdots O$ hydrogen-bonding interactions.

Comment

1,4-Dihydropyridine (1,4-DHP) derivatives have yielded many drugs which act as calcium channel agonists or antagonists (Rose, 1989, 1990). Nifedipine is the prototype of this group, and both it and its structural analogues are used as antianginal and antihypertensive drugs (Janis & Triggle, 1984). Our interest is in the correlation between the three-dimensional structure and calcium antagonistic behaviour of condensed derivatives of 1,4-DHP (Linden *et al.*, 1998, 2002, 2004, 2005; Şimşek *et al.*, 2000, 2003; Kismetli *et al.*, 2004). Two new compounds have been prepared as further potentially active 1,4-DHP derivatives. These compounds differ only in the substituent at the 7-position of the cyclohexenone ring and are methyl 4-(2,4-dichlorophenyl)-2,7-dimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate, (I), and methyl

4-(2,4-dichlorophenyl)-2-methyl-7-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate monohydrate, (II). The syntheses are not stereospecific, so the reactions produced mixtures of the 4,7-diastereoisomers of the racemic compounds. The stereoisomers could not be separated readily and, as subsequently revealed by the crystal structure determinations, crystallization yielded cocrystals in which both diastereoisomers were incorporated, rather than crystals of a single compound forming preferentially.



Views of the asymmetric units in the structures of (I) and (II) are shown in Figs. 1 and 2, respectively. Compound (II) crystallizes as the monohydrate, in which the water molecule is disordered over two sites. The centrosymmetric space groups indicate that the compounds are racemic. Although there is only one formula unit in the asymmetric unit of each structure, the molecules are disordered at atom C7 of the oxocyclohexene rings [and at atom C6 in (II)] and the disorder extends through the substituents at C7 [methyl in (I) and phenyl in (II)]. The disorder manifests itself as alternate directions of folding of the flap of the C7-envelope [in (I)] or half-chair [in (II)] conformations of the cyclohexenone rings, but inspection of the positions of the substituents indicates that the two arrangements are related by inversion of the configuration at atom C7. As the configuration at atom C4 is constant in both of the disordered arrangements, the disorder is actually a consequence of the presence of a mixture of diastereoisomers




Figure 1

A view of the molecule of (I), showing the atom-labelling scheme and the disorder resulting from the occurrence of diastereoisomers at the same crystallographic site. Displacement ellipsoids are drawn at the 40% probability level. Some of the disordered H atoms have been omitted for clarity.

in the crystal. The diastereoisomers with the same configuration at atom C4 have been inserted randomly and in almost equal quantities in the crystal lattice and the centrosymmetric space group accommodates the enantiomers of the diastereoisomeric pair. If the diastereoisomers were incorporated into the crystal lattice in a regular sequence, one would find two molecules (at least) in the asymmetric unit. That a random distribution of diastereoisomers occurs in the crystal suggests that the shape of the volume occupied by the diastereoisomeric molecules is very similar.

Despite the disorder, most of the bond lengths and angles in (I) and (II) have normal values. There are small angular distortions about atoms C2 and C10 (Tables 1 and 3), which result from steric interactions between the methyl substituent at C2 and atom O10 of the ester substituent at C3 [O10...C9 = 2.790 (4) and 2.814 (5) Å for (I) and (II), respectively]. The presence of π -electron conjugation keeps the ester group at C3 almost coplanar with the endocyclic double bond [C2=C3—C10=O10 = -2.7 (4) and 0.6 (5)° for (I) and (II), respectively] and prevents the ester group from rotating into a sterically more amenable orientation. These properties are consistent with those of related compounds (Linden *et al.*, 2005).

The switch from the 7-methyl substituent in compound (I) to the 7-phenyl substituent in compound (II) has no major influence on the conformations of the molecules. The 1,4-DHP rings have the shallow boat conformation generally observed for 4-aryl-1,4-DHP derivatives (Linden *et al.*, 2005), although the conformations in (I) and (II) are among the shallowest examples. In compound (I), atoms N1 and C4 are 0.035 (2) and 0.115 (2) Å, respectively, from the plane defined by atoms C2, C3, C4A and C8A. The deviation of atom N1 from this plane is so small that the ring could almost be described as having a shallow envelope conformation. The corresponding displacements in compound (II) are 0.058 (3) and 0.200 (3) Å, respectively. The shallowness of the boat conformations is indicated by the small values of the total puckering amplitudes, Q (Cremer & Pople, 1975), of 0.090 (3) and 0.141 (3) Å

for compounds (I) and (II), respectively. Three structures of 1,4-DHP derivatives with similarly shallow boat conformations were reported recently (Quesada *et al.*, 2006) and several examples containing a planar ring are also known (Pastor *et al.*, 1994; Duque *et al.*, 2000; Low *et al.*, 2001; Linden *et al.*, 2002; Mahendra *et al.*, 2003).

The plane of the 2,4-dichlorophenyl ring in each of the title compounds is, as frequently observed (Linden *et al.*, 2005), essentially parallel to the N1...C4 axis. Compound (I) has a N1...C4—C13—C18 pseudo-torsion angle of 2.6 (3)°, while the corresponding torsion angle in compound (II) is 1.8 (3)°. The 2-chloro substituent lies above the C4—H bond in the sterically most favourable synperiplanar orientation. The Cambridge Structural Database (Release 5.27, with January 2006 updates; Allen, 2002) contains five examples of 4-aryl-1,4-DHP compounds with 2,4-disubstitution in the phenyl ring. Three of these compounds are 3,5-dicarboxy-4-(2,4-dichlorophenyl)-2,6-dimethyl-1,4-DHP derivatives (Mehdi & Ravikumar, 1992; Sagar *et al.*, 1999; Caignan & Holt, 2000), while there is one 4-(2-chloro-4-nitrophenyl)- (Rovnyak *et al.*, 1988) and one 4-(2,4-dinitrophenyl)- analogue (Fossheim *et al.*, 1982). In each of these compounds, the 2,4-disubstituted phenyl ring has a synperiplanar orientation with respect to the 1,4-DHP ring, although with the 4-(2,4-dinitrophenyl)- derivative and one of the 4-(2,4-dichlorophenyl)- derivatives (Sagar *et al.*, 1999), the plane of the phenyl ring is rotated slightly to make angles of about 16 and 31°, respectively, with the N1...C4 axis.

The use of geometric restraints to handle the disordered atoms in the structures of (I) and (II) makes it unwise to analyse the conformations of the cyclohexenone rings in any detail. It suffices to say that the cyclohexenone ring in each diastereoisomer of compound (I) has a C7-envelope conformation, while the corresponding conformation in each diastereoisomer of compound (II) is that of a slightly distorted half-chair twisted about the C6—C7 bond. It has been noted previously that atom C7 is the atom that deviates most from the ring plane in structures involving the quinolin-5-one or acridine-1,8-dione moiety (Linden *et al.*, 2005).

In compound (I), an intermolecular N—H...O hydrogen bond between the amine group and the carbonyl O atom of the cyclohexenone ring of a neighbouring molecule (Table 2) links the molecules into extended chains which run parallel to the [101] direction and can be described by a graph-set motif of $C(6)$ (Bernstein *et al.*, 1995). The same $C(6)$ motif has been observed in the crystal structures of several other closely related 1,4-DHP compounds (Linden *et al.*, 1998, 2002, 2004, 2005; Şimşek *et al.*, 2000). In compound (II), the major site of the disordered water molecule accepts the N—H...O hydrogen bond from the 1,4-DHP molecule and, in turn, forms another intermolecular hydrogen bond with the carbonyl O atom of the cyclohexenone ring of a neighbouring 1,4-DHP molecule (Table 4). These interactions link the 1,4-DHP and water molecules alternately into extended chains which run parallel to the [100] direction and can be described by a binary graph-set motif of $C_2^2(8)$. The minor site of the water molecule (12% occupancy) has not been considered in this analysis.




Figure 2

A view of the molecule of (II), showing the atom-labelling scheme and the disorder resulting from the occurrence of diastereoisomers at the same crystallographic site. Displacement ellipsoids are drawn at the 40% probability level. Some of the disordered H atoms have been omitted for clarity.

For (II), the disorder of the phenyl-substituted atom of the cyclohexenone ring and its associated phenyl group, as well as an adjacent methylene group, was treated exactly as described above. The site-occupation factor for the atoms corresponding to the major isomer refined to 0.505 (7). The asymmetric unit also contains a water molecule disordered over two adjacent positions and the site-occupation factor of the more occupied site refined to 0.879 (6). The H atoms of the lesser occupied site were not included in the model.

The position of the amine H atom for each structure and the positions of the H atoms of the major occupied site of the water molecule in (II) were determined from a difference Fourier map and refined freely with individual isotropic displacement parameters. The methyl H atoms were constrained to an ideal geometry, with C—H = 0.98 Å and $U_{\text{iso}}(\text{H}) = 1.5U_{\text{eq}}(\text{C})$, but were allowed to rotate freely about their C—C bonds. All other H atoms were placed in geometrically idealized positions and constrained to ride on their parent C atoms at distances of 0.95, 0.99 or 1.00 Å for phenyl, methylene or methine groups, respectively, and with $U_{\text{iso}}(\text{H}) = 1.2U_{\text{eq}}(\text{C})$.

For both compounds, data collection: *COLLECT* (Nonius, 2000); cell refinement: *DENZO-SMN* (Otwinowski & Minor, 1997); data reduction: *DENZO-SMN* and *SCALEPACK* (Otwinowski & Minor, 1997); program(s) used to solve structure: *SIR92* (Altomare *et al.*, 1994); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *ORTEPII* (Johnson, 1976); software used to prepare material for publication: *SHELXL97* and *PLATON* (Spek, 2003).

Supplementary data for this paper are available from the IUCr electronic archives (Reference: SK3008). Services for accessing these data are described at the back of the journal.

References

- Allen, F. H. (2002). *Acta Cryst.* **B58**, 380–388.
 Altomare, A., Cascarano, G., Giacovazzo, C., Guagliardi, A., Burla, M. C., Polidori, G. & Camalli, M. (1994). *J. Appl. Cryst.* **27**, 435.
 Bernstein, J., Davis, R. E., Shimon, L. & Chang, N.-L. (1995). *Angew. Chem. Int. Ed. Engl.* **34**, 1555–1573.
 Blessing, R. H. (1995). *Acta Cryst.* **A51**, 33–38.
 Caignan, G. A. & Holt, E. M. (2000). *J. Chem. Crystallogr.* **30**, 677–684.
 Cremer, D. & Pople, J. A. (1975). *J. Am. Chem. Soc.* **97**, 1354–1358.
 Duque, J., Pomés, R., Suárez, M., Ochoa, E., Verdecia, Y., Ponte, G. & Echevarría, G. (2000). *Z. Kristallogr. New Cryst. Struct.* **215**, 361–362.
 Fossheim, R., Svarteng, K., Mostad, A., Romming, C., Shefter, E. & Triggle, D. J. (1982). *J. Med. Chem.* **25**, 126–131.
 Janis, R. A. & Triggle, D. J. (1984). *Drug Dev. Res.* **4**, 257–274.
 Johnson, C. K. (1976). *ORTEPII*. Report ORNL-5138. Oak Ridge National Laboratory, Tennessee, USA.
 Kismetli, E., Şafak, C., Erol, K., Sirmagül, B. & Linden, A. (2004). *Arzneim. Forsch. (Drug Res.)*, **54**, 371–375.
 Linden, A., Şafak, C. & Aydın, F. (2004). *Acta Cryst.* **C60**, o711–o713.
 Linden, A., Şafak, C. & Kismetli, E. (2002). *Acta Cryst.* **C58**, o436–o438.
 Linden, A., Şafak, C. & Şimşek, R. (1998). *Acta Cryst.* **C54**, 879–882.
 Linden, A., Şimşek, R., Gündüz, M. & Şafak, C. (2005). *Acta Cryst.* **C61**, o731–o734.
 Low, J. N., Cobo, J., Nogueras, M., Sánchez, A., Quiroga, J. & Mejía, D. (2001). *Acta Cryst.* **C57**, 1356–1358.
 Mahendra, M., Doreswamy, B. H., Adlakha, P., Raval, K., Varu, B., Shah, A., Sridhar, M. A. & Prasad, J. S. (2003). *Anal. Sci.* **19**, x55–x56.
 Mehdi, S. & Ravikumar, K. (1992). *Acta Cryst.* **C48**, 1627–1630.
 Nonius (2000). *COLLECT*. Nonius BV, Delft, The Netherlands.
 Otwinowski, Z. & Minor, W. (1997). *Methods in Enzymology*, Vol. 276, *Macromolecular Crystallography*, Part A, edited by C. W. Carter Jr & R. M. Sweet, pp. 307–326. New York: Academic Press.
 Pastor, A., Alajarin, R., Vaquero, J. J., Alvarez-Builla, J., Fau de Casa-Juana, M., Sunkel, C., Priego, J. G., Fonseca, I. & Sanz-Aparicio, J. (1994). *Tetrahedron*, **50**, 8085–8098.
 Quesada, A., Argüello, J., Squella, J. A., Wardell, J. L., Low, J. N. & Glidewell, C. (2006). *Acta Cryst.* **C62**, o8–o12.
 Rose, U. (1989). *Arzneim. Forsch. (Drug Res.)*, **39**, 1393–1398.
 Rose, U. (1990). *Arch. Pharm. (Weinheim)*, **323**, 281–286.
 Rovnyak, G., Andersen, N., Gougoutas, J., Hedberg, A., Kimball, S. D., Malley, M., Moreland, S., Porubcan, M. & Pudzianowski, A. (1988). *J. Med. Chem.* **31**, 936–944.
 Sagar, M. B., Ravikumar, K., Mehdi, S., Sadanandam, Y. S., Giju, K. T. & Jemmis, E. D. (1999). *J. Chem. Crystallogr.* **29**, 481–491.
 Sheldrick, G. M. (1997). *SHELXL97*. University of Göttingen, Germany.
 Şimşek, R., Linden, A. & Şafak, C. (2000). *Acta Cryst.* **C56**, 351–353.
 Şimşek, R., Şafak, C., Erol, K., Ataman, Ş., Ülgen, M. & Linden, A. (2003). *Arzneim. Forsch. (Drug Res.)*, **53**, 159–166.
 Spek, A. L. (2003). *J. Appl. Cryst.* **36**, 7–13.